OncoSec Medical (ONCS) Receiving Somewhat Favorable News Coverage, Analysis Shows
Headlines about OncoSec Medical (NASDAQ:ONCS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoSec Medical earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.4432487271411 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
OncoSec Medical (ONCS) opened at 0.99 on Wednesday. OncoSec Medical has a 12-month low of $0.88 and a 12-month high of $2.08. The company’s market cap is $20.96 million. The stock’s 50 day moving average is $0.98 and its 200-day moving average is $1.11.
ONCS has been the subject of a number of research reports. ValuEngine lowered shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Dawson James reissued a “buy” rating and set a $5.00 target price on shares of OncoSec Medical in a research note on Thursday, July 6th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of OncoSec Medical in a research note on Friday, June 2nd. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a research note on Wednesday, June 14th. Finally, Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of OncoSec Medical in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $5.33.
WARNING: “OncoSec Medical (ONCS) Receiving Somewhat Favorable News Coverage, Analysis Shows” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://theolympiareport.com/2017/09/20/oncosec-medical-oncs-receiving-somewhat-favorable-news-coverage-analysis-shows.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.